173 related articles for article (PubMed ID: 37639064)
1. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer: A Single-Institution Study.
Kong ZQ; Liu LQ; Huang Q; Wang YT; Li JJ; Zhang Z; Wang XX; Liu CL; Zhang YD; Shao JK; Zhu YM; Chen YM; Liu M; Zhao WH
Biomed Environ Sci; 2024 May; 37(5):457-470. PubMed ID: 38843919
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
7. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
9. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
10. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
11. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor status.
Xu B; Shen J; Shen J; Wang L
Int J Clin Oncol; 2023 Apr; 28(4):543-549. PubMed ID: 36723789
[TBL] [Abstract][Full Text] [Related]
13. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.
Sun T; Wang T; Li X; Wang H; Mao Y
Front Oncol; 2023; 13():1148228. PubMed ID: 37409261
[TBL] [Abstract][Full Text] [Related]
15. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
17. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1.
Yue M; Wu S; Wang X; Cai L; Wang X; Yang H; Liu Y
Pathol Res Pract; 2023 Jul; 247():154532. PubMed ID: 37267721
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis.
Petrelli F; Rea C; Parati MC; Borgonovo K; Ghilardi M; Dottorini L; Luciani A; Ghidini M; Ruatta F; Garrone O; Tomasello G
Anticancer Res; 2023 Oct; 43(10):4303-4313. PubMed ID: 37772569
[TBL] [Abstract][Full Text] [Related]
19. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
